Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development. By combining molecular targeting with controlled radiation delivery, these therapies introduce a ...

ProMIS Neurosciences Inc., a clinical-stage biotechnology firm, announced its plan to present preclinical data on novel computationally-derived vaccines targeting neurodegenerative diseases at the ...

– Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary Sclerosing Cholangitis (PSC) and Related Diseases – – ...

Boehringer Ingelheim and the Lower Franconian biotech company EMFRET Analytics have signed a cooperation and license ...

“Editas Medicine is making significant progress towards the clinic with our in vivo medicines in preclinical development for people living with serious diseases,” said Linda C. Burkly, Ph.D., ...

Lilly licenses Insilico's AI drug discovery platform in a deal worth up to $2.75B, signaling a shift in how novel ...

The pharmaceutical industry has long operated on a one-size-fits-all model, developing drugs primarily tested on, and thus best suited for, people of European descent. This approach ignores — and ...

By incorporating these advanced models into preclinical packages for the FDA, researchers can provide a much stronger proof ...

- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the ...

LILLE, France & PARIS--(BUSINESS WIRE)--Regulatory News: Dev4All, 4P-Pharma's cutting-edge R&D booster, announces a strategic collaboration with Pharmaseed, an established Contract Research ...

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), an ...